Shuttle Pharmaceuticals Faces Nasdaq Delisting Risk Over Equity Shortfall

Reuters11-18
Shuttle Pharmaceuticals Faces Nasdaq Delisting Risk Over Equity Shortfall

Shuttle Pharmaceuticals Holdings Inc. has announced that it was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintain a minimum of $2.5 million in stockholders' equity. The company reported stockholders' equity of $1,394,161 as of September 30, 2025. However, Shuttle Pharmaceuticals believes it has regained compliance following a private placement on November 4, 2025, which raised approximately $2.5 million in gross proceeds. Nasdaq will continue to monitor the company's compliance, and if it is not maintained by the next periodic report, Shuttle Pharmaceuticals may face delisting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-023845), on November 17, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment